
BBNX Stock Forecast & Price Target
BBNX Analyst Ratings
Bulls say
Beta Bionics is in a strong financial position with a solid cash balance to support its sales team expansion and R&D initiatives. The increase in pharmacy new patient starts is a positive sign for the company's financial performance in the coming quarters and years. With the company's positive clinical trial results and upcoming product launches, we believe Beta Bionics has a compelling investment opportunity with a potential for market share gains and revenue growth.
Bears say
Beta Bionics is facing operational and market risks amidst a slowdown in its net promoter score and a recent FDA warning letter. Despite an optimistic outlook for the iLet Bionic Pancreas and potential growth in the pharmacy channel and Type 2 diabetes market, the company's stock has been on a downtrend due to the NPS miss and regulatory uncertainties. With a current valuation at a discount to its peer group and potential for re-acceleration in NPS momentum and progress on its new patch pump, the stock offers favorable risk-reward.
This aggregate rating is based on analysts' research of Beta Bionics Inc and is not a guaranteed prediction by Public.com or investment advice.
BBNX Analyst Forecast & Price Prediction
Start investing in BBNX
Order type
Buy in
Order amount
Est. shares
0 shares